GLP 3 (RT) / GLP 2 (TZ) (30mg / 5mg)
For Research Use Only — Not for Human Use
Intended for laboratory research use only (e.g., analytical and in-vitro studies). Not for human use.
GLP 3 (RT) / GLP 2 (TZ) is a dual-peptide research blend combining a GIP/GLP-1/glucagon triple-receptor agonist (GLP 3 (RT)) with a dual GIP/GLP-1 receptor agonist (GLP 2 (TZ)).
Researchers use this combination to study overlapping incretin, glucagon, and nutrient-sensing receptor signaling under controlled laboratory conditions.
This compound is provided by GENIQ exclusively for scientific research and not for human or animal use.
$379.99
-
Official retailer -
Quality guaranteed
-
Free delivery from $99
-
Free returns is available
What Is GLP 3 (RT) / GLP 2 (TZ)?
GLP 3 (RT) / GLP 2 (TZ) is a synthetic peptide blend developed for research on multi-receptor metabolic signaling.
GLP 3 (RT) is engineered to engage GIP, GLP-1, and glucagon receptors simultaneously, while GLP 2 (TZ) is a dual GIP/GLP-1 receptor agonist. Both carry a fatty-diacid side chain that extends their duration within experimental systems.
Researchers use this blend to investigate combined incretin-receptor activation, glucose-regulation models, and energy-balance pathways in vitro and in preclinical settings.
GENIQ provides this compound solely for controlled laboratory research, not for human or animal use.
Peptide Overview
This blend merges two peptides commonly used in metabolic signaling research:
GLP 3 (RT):
A 39-amino-acid triple agonist studied for its simultaneous activity at GIP, GLP-1, and glucagon receptors and its influence on nutrient-sensing and energy-expenditure models.
GLP 2 (TZ):
A 39-amino-acid dual GIP/GLP-1 receptor agonist investigated for incretin-pathway signaling, insulin-secretion modeling, and receptor-selectivity studies.
| Laboratory studies evaluate how this peptide combination may influence: |
| • Incretin-receptor activation and cAMP signaling |
| • Glucose-regulation and insulin-secretion models |
| • Glucagon-receptor-mediated energy-expenditure pathways |
| • Nutrient-sensing and appetite-signaling circuits in preclinical models |
| These findings are strictly from research environments. |
All findings remain limited to preclinical and in-vitro experimental environments.
History of GLP 3 (RT) / GLP 2 (TZ)
GLP 2 (TZ) emerged from efforts to combine GIP and GLP-1 receptor activity within a single molecule, building on earlier single-agonist incretin research. Its dual-receptor profile made it a widely used reference compound in metabolic studies.
GLP 3 (RT) was developed subsequently as a triple agonist, adding glucagon-receptor activity to the GIP/GLP-1 framework to explore whether a broader receptor profile changes energy-balance outcomes in experimental models.
Researchers began pairing the two compounds to compare dual versus triple incretin-receptor engagement within the same experimental framework. The combination remains of interest for in-vitro and preclinical examination of metabolic receptor signaling.
Peptide Structure
GLP 3 (RT):
39-amino-acid GIP/GLP-1/glucagon receptor triple agonist with a C20 fatty-diacid side chain
Molecular Formula: C221H342N46O68
GLP 2 (TZ):
39-amino-acid GIP/GLP-1 receptor dual agonist with a C20 fatty-diacid side chain
Molecular Formula: C225H348N48O68
Certificates of Analysis
GLP 3 (RT) / GLP 2 (TZ) (30mg / 5mg)
Research Findings
Research models analyzing the dual activity of GLP 3 (RT) and GLP 2 (TZ) commonly explore:
| • Multi-receptor incretin signaling: Comparing dual versus triple receptor engagement in the same experimental system. |
| • Glucose-regulation modeling: Examining insulin-secretion and glucose-disposal responses in preclinical models. |
| • Energy-balance pathways: Studying glucagon-receptor-mediated effects on energy expenditure and lipid metabolism in vitro. |
| • Receptor pharmacology: Investigating binding kinetics, cAMP accumulation, and downstream gene-expression changes. |
| These data represent controlled in-vitro and preclinical studies, not clinical outcomes. |
These findings reflect laboratory experiments only and do not indicate clinical outcomes.
References
FAQ
Are GENIQ peptides pharmaceutical products?
No. They are not drugs, supplements, or therapeutic items. All compounds are provided strictly for laboratory research.
Who should purchase GENIQ research materials?
Qualified researchers, laboratories, and institutions working within applicable laws and regulations.
Do orders include COAs?
Yes. Each peptide includes a Certificate of Analysis confirming identity and purity testing when available for that lot.
What handling notes does GENIQ provide?
Only storage temperature and solvent-compatibility notes when listed on the product page. GENIQ does not provide guidance on preparation or application. Buyers follow their institution’s laboratory protocols.
Are these products for human use?
No. For Research Use Only — Not for Human Use. Not for human or animal consumption.
For Research Use Only — Not for Human Use
Sold exclusively as laboratory research materials. Not for human or animal consumption, clinical use, or household use.
Intended research use: Laboratory and in-vitro research, including analytical characterization and pathway / receptor-binding studies as applicable to this compound. Not for human consumption, clinical use, or diagnostic use on humans.
GLP 3 (RT) / GLP 2 (TZ) is a dual-peptide research blend combining a GIP/GLP-1/glucagon triple-receptor agonist (GLP 3 (RT)) with a dual GIP/GLP-1 receptor agonist (GLP 2 (TZ)).
Researchers use this combination to study overlapping incretin, glucagon, and nutrient-sensing receptor signaling under controlled laboratory conditions.
This compound is provided by GENIQ exclusively for scientific research and not for human or animal use.
RELATED PRODUCTS
Glutathione
Price range: $99.99 through $175.99
